HMP Global, the leading omnichannel healthcare company, today announced the GI Cancers Alliance, Inc. as a partner for the 2024 World Congress on Gastrointestinal Cancer, the premier international forum for GI cancer professionals committed to understanding the very latest research, engaging in global exchange, and advancing clinical outcomes.
Details
Bristol Myers Squibb today announced that Opdivo® (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Details
Bayer and NeoGenomics launch the Test4TRK™ Program to provide genomic cancer testing at no cost for people living with advanced thyroid and colorectal cancers.
Details
Bristol Myers Squibb Company today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S.
Details
The Chan Zuckerberg Initiative (CZI) announced that the Fibrolamellar Cancer Foundation (FCF) is among a select group of patient-led rare.
Details
Catch up on our investigator-initiated clinical trials. Ruesch Center faculty and their NIH collaborators are really making an effort to change the standard of care.
Details
The Treatment and Survivorship Care Plan was devised by the GI Cancers Alliance, a group of advocacy organizations, health care professionals and industry partners working to boost awareness and education about these cancers and to advocate for their prevention, treatment and cure.
Details
Understanding the need for increased GI cancer patient education, the GI Cancers Alliance created an online unmet needs survey with goals that included: determining gaps in support services, better understanding needs in patient education, and gaining insight into psychosocial concerns.
Details
When Martha Raymond, M.A., CPN, executive director of Michael’s Mission and co-chair of the GI Cancers Alliance, conducted an anonymous online survey to explore the unmet needs of patients with gastrointestinal (GI) cancers, she was shocked at their gut wrenchingly honest and disheartening responses.
Details
In this CURE Connections® program, Philippa Cheetham, MD, interviews key thought leaders of the GI Cancers Alliance, a coalition of organizations that have joined together to raise awareness, provide education, and accelerate the research and development of treatments in the area of gastrointestinal cancers.
Details